Antiphospholipid syndrome;Síndrome antifosfolípide

Anais Brasileiros de Dermatologia

Volumn 80, Issue 3, 2005, Pages 225-239

  Santamaria, Jesus Rodriguez ^a,b,d   Mandelli, Fernando Luiz ^c   Badziak, Daniela ^c   Cavalin, Leila Cristina ^c   De Barros, Michelle Ferreira ^c   Sato, Maurício Shigueru ^c  

^a Disciplina de Gastroenterologia   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^d NONE   (Brazil)

Author keywords

Antiphospholipid syndrome; Skin manifestations; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FETUS WASTAGE; HUMAN; INFECTION; LIVEDO RETICULARIS; RECURRENT DISEASE; REVIEW; SEROLOGY; SKIN DEFECT; SKIN ULCER; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS; VEIN THROMBOSIS;

EID: 22644434182     PISSN: 03650596     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0365-05962005000300002     Document Type: Review

References (62)

1. Marai I, Zandman-Goddard G, Schoenfeld Y. The systemic nature of antiphospholipid syndrome. Scand J Rheumatol. 2004; 33: 365-72.
2. Gibson GE, Su WP, Pittelkow MR. Antiphospholipid syndrome and the skin. J Am Acad Dermatol. 1997; 36: 970-82.
3. Wassermann A, Neisser A, Bruck C. Eine serodiagnostiche reaktion bey syphilis. Deuts Che Méd Wochenschr. 1906; 32: 745-2.
4. Pangborn MC. A new serologically active phospholipid from beef heart. Proc Soc Exp Biol Méd. 1941; 48: 484-6.
5. Conley CL, Hartmann RC. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest. 1952; 31: 621-2.
6. Bowie EJW, Thompson JH, Pascuzzi CA, Owen CA. Thrombosis in systemic lupus erythematosus despite circulating antibodies. J Lab Clin Méd. 1963; 62: 416-30.
7. Feinstein DI, Rapaport SI. Acquired Inhibitors of blood coagulation. Prog Hemost Thromb. 1972; 1: 75-95.
8. Nilsson IM, Astedt B, Hedner U, Berezine D. Intrauterine death and circulating anticoagulant "antithromboplastin". Acta Méd Scand. 1975; 197: 153-9.
9. Hughes GR. The anticardiolipin syndrome. Clin Exp Rheumatol. 1985; 3:285-6.
10. Harris EM, Hughes GR, Gharavi AE. Antiphospholipid antibodies: an elderly statesman dons new garments. J Rheumatol. 1987; 13: S208-13.
11. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet. 1990; 335: 1544-7.
12. McNeil HP, Simpson RJ, Chesterman CN, Krilis AS. Anti-phospholipid antibodies are direct against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta-2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA. 1990; 87: 4120-4.
13. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis then anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003; 101: 1827-32.
14. Fessler BJ. Thrombotic syndromes and auto immunes diseases. Rheum Dis Clin North Am. 1997; 23:461-79.
15. Zanon E, Saggiorato G, Ramon R. Anti-prothrombin antibodies as a potential risk factor of recurrent venous thromboembolism. Thromb Haemost. 2004; 91: 255-8.
16. Hojnik M, George J, Ziporen L, Shoenfeld Y. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation. 1996; 93: 1579-87.
17. Asherson RA, Cervera R, Piette JC, Shoenfeld Y, Espinosa G, Petri MA, et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore). 2001; 80: 355-77.
18. Ruiz-Irastorza G, Egurbide My Aguirre C. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med. 2004; 164: 77-82
19. Derksen RH, Khamashta MA, Branch DW. Management of the obstetric antiphospholipid syndrome. Arthritis Rheum. 2004; 50: 1028-39.
20. Cervera R, Piette JC, Fornt J. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002; 46: 1019-27.
21. Nahass GT. Antiphospholipid antibodies and the antiphospholipid antibody syndrome. J Am Acad Dermatol. 1997; 36: 149-71.
22. Goldberg SN, Conti-Kelly AM, Greco T. A family study of anticardiolipin antibodies and associated clinical conditions. Am J Med. 1995; 99: 473-9.
23. Sebastiani GD, Galeazzi M, Morozzi G, Marcolongo R. The immunogenetics of the antiphospholipid syndrome, anticardiolipin antibodies, and lupus anticoagulant. Semin Arthritis Rheum. 1996; 25: 414-20.
24. McNeil HP, Chesterman CN, Krilis AS. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol. 1991; 49: 193-280.
25. Petri M. Pathogenesis and treatment of the antiphospholipid antibody syndrome. Med Clin North Am. 1997; 81: 151-77.
26. Salmon JE, Girrardi G. The role of complement in the antiphospholipid syndrome. Curr Dir Autoimmun. 2004; 7: 133-48.
27. Simantov R, LaSala JM, Lo SK, Gharavi AE, Sammaritano LR, Salmon JE, et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest. 1995; 96: 2211-9.
28. Carmo-Pereira S, Bertolaccini ML, Escudero-Contreras A. Value of IgA anticariolipin and anti-beta 2-glycoprotein I antibody testing in patients with pregnancy morbidity. Ann Rheum Dis. 2003; 62: 540-3.
29. Gezer S. Antiphospholipid Syndrome. Dis Mon. 2003; 49: 696-741.
30. Cuadrado MJ, Hughes GRV. Hughes (antiphospholipid) syndrome. Clinical features. Rheum Dis Clin North. Am 2001; 27: 507-24.
31. Amigo MC, Khamashta MA. Antiphospholipid (Hughes) syndrome in systemic lupus erythematosus. Rheum Dis Clin North Am. 2000; 26: 331-48.
32. Hanly JG. Antiphospholipid syndrome. An overview. CMAJ. 2003; 168: 1675-82.
33. Mulinari-Brenner FA, Pizzol ASD, Manfrinato LC, Santamaria JR, Gemelli JJ. An Bras Dermatol. 2000; 75: 219-24.
34. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med. 2002; 346: 752-63.
35. Diógenes MJN, Diógenes PCN, Carneiro RMM, et al. Cutaneous manifestations associated with antiphospholipid antibodies. Int J Dermatol. 2004; 43: 632-7.
36. Alegre VA, Winkelmann RK, Gastineau DA. Cutaneous thrombosis, cerebrovascular thrombosis and lupus anticoagulant - the Sneddon syndrome. Report of 10 cases. Int J Dermatol. 1990; 29: 45-9.
37. Levine SR, Langer SL, Albers JW, Welch KMA. Sneddon's syndrome: an antiphospholipid antibody syndrome?. Neurology. 1988; 38: 798-800.
38. Gantcheva M. Dermatologic aspects of antiphospholipid syndrome. Int J Dermatol. 1998; 37: 173-80.
39. Galli M. Antiphospholipid syndrome: association between laboratory tests and clinical practice. Pathophysiol Haemost Thromb. 2004; 33: 249-55.
40. Greaves M. Antiphospholipid antibodies and thrombosis. Lancet. 1999; 353: 1348-53.
41. Amengual O, Atsumi T, Koike T. Antiprothrombin antibodies and the diagnosis of antiphospholipid syndrome. Clin Immun. 2004; 112: 144-9.
42. Myers B, Gould J. The place of beta 2 glycoprotein 1 in the assessment of antiphospholipid syndrome. Blood Coagul Fibrinolysis. 2003; 14: 1-2.
43. Reddel SW, Krilis AS. Testing for and clinical significance of anticardiolipin antibodies. Clin Diagn Lab Immunol. 1999; 6: 775-82.
44. Obermoser G, Bitterlich W, Kunz F, Sepp NT. Clinical significance of anticardiolipin and anti-beta 2-glycoprotein antibodies. Int Arch Allergy Immunol. 2004; 135: 148-53.
45. Alving BM. Diagnosis and management of patients with the antiphospholipid syndrome. J Thromb Thromboly. 2001; 12: 89-93.
46. Rodgers GM. Thrombosis and antithrombotic therapy. In Lee GR, Foersten J, Kukens J, et al. Editors. Wintrobe Clinical Hematology. Baltimore: Williams & Wilkins; 1999. p.1781-820.
47. Golan TD. Lupus vasculitis: differential diagnosis with antiphospholipid syndrome. Curr Rheumatol Rep. 2002; 4: 18-24.
48. Asherson RA. The catastrophic antiphospholipid (Asherson's syndrome) in 2004 - a review. Autoimmune Rev. 2005; 4: 48-54.
49. Alving BM, Barr CF, Tang DB. Correlation between lupus anticoagulants and anticardiolipin antibodies in patients with prolongated activated partial thrombo plastin times. Am J Méd. 1990; 88: 112-6.
50. Loskshin MD, Erkan D. Treatment of the antiphospholipid syndrome. N Engl J Méd. 2003; 349: 1133-8.
51. Luzzana C, Gerosa M, Riboldi P, Meroni PL. Update on the antiphospholipid syndrome. J Nephrol. 2002; 15: 342-8.
52. Lassere M, Empson M. Treatment of antiphospholipid syndrome in pregnants-a systematic review of randomized therapeutic trial. Thrombosis Research. 2004; 114: 419-26.
53. Goldhaber SZ. Pulmonary embolism. N Engl J Med. 2005; 339: 93-102.
54. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 1995; 332: 993-7.
55. Crowther MA, Ginsberg JS, Julian J, Math. M, Denburg J, Hirsh J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003; 349: 1133-8.
56. Crowther M, Wisloff F. Evidence based treatment of the antiphospholipid syn drome. Optimal anticoagulant therapy for thrombosis. Thrombosis Research. 2005; 115: 3-8.
57. Tektonidou MG, Ioannidis JP, Boki KA, Vlachoyiannopoulos PG, Moutsopoulos HM. Prognostic factors and clustering of serious clinical outcomes in antiphospholipid syndrome. Q J Med. 2000; 93: 525-30.
58. Buhler-Singer S, von Hintzenstern J, Fartasch M, Hornstein OP Anticardiolipin syndrome with only skin envolvement. Hautzart. 1994; 45: 394-7.
59. Piette WW. Antiphospholipid antibody syndrome: the problems and the promise. Br J Dermatol. 2000; 142: 1080.
60. Finazzi G, Brancaccio V, Moia M, Ciaverella N, Mazzucconi MG, Schinco PC, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four year prospective study from the italian register. Am J Med. 1996; 100: 530-6.
61. Rosove MH, Petronella MC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Int Med. 1992; 117: 303-8.
62. Camps Garcia MT, Gutierrez Rueda A, Guil Garcia M, Perello-Gonzalez Moreno I, Garcia Portales R, Belmonte Lopez A, et al. Clinical and analytical manifestations of primary antiphospholipid antibody syndrome. An Med Interna. 1993; 10: 576-82.